Literature DB >> 21150277

Do predictive signatures really predict response to cancer chemotherapy?

Piet Borst1, Lodewyk Wessels.   

Abstract

Predictive signatures are gene expression profiles that should predict the response of tumors to chemotherapy in patients. Such signatures have been derived from the response of tumor cell lines to chemotherapy, but their usefulness in patients remains controversial, as the most spectacular published signatures are based on unreliable data. We discuss why it is difficult to derive meaningful predictive signatures from cell line panels and we argue that it is implausible that fully predictive signatures can be obtained for classical chemotherapy from oligo-based gene expression arrays. One reason is that resistance to chemotherapy can be caused by alterations in (the expression of) a single gene. We do not expect that such subtle alterations will be reliably picked up by standard gene expression profiling. We delineate alternative approaches that should be able to yield predictive markers that can be used for optimizing patient treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21150277     DOI: 10.4161/cc.9.24.14326

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  28 in total

1.  Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Authors:  Jean-Pierre Gillet; Anna Maria Calcagno; Sudhir Varma; Miguel Marino; Lisa J Green; Meena I Vora; Chirayu Patel; Josiah N Orina; Tatiana A Eliseeva; Vineet Singal; Raji Padmanabhan; Ben Davidson; Ram Ganapathi; Anil K Sood; Bo R Rueda; Suresh V Ambudkar; Michael M Gottesman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-08       Impact factor: 11.205

2.  The clinical relevance of cancer cell lines.

Authors:  Jean-Pierre Gillet; Sudhir Varma; Michael M Gottesman
Journal:  J Natl Cancer Inst       Date:  2013-02-21       Impact factor: 13.506

3.  Gene signatures in breast cancer: current and future uses.

Authors:  Enrique Espinosa Arranz; Juan Ángel Fresno Vara; Angelo Gámez-Pozo; Pilar Zamora
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

4.  Integration of Tumor Genomic Data with Cell Lines Using Multi-dimensional Network Modules Improves Cancer Pharmacogenomics.

Authors:  James T Webber; Swati Kaushik; Sourav Bandyopadhyay
Journal:  Cell Syst       Date:  2018-11-07       Impact factor: 10.304

5.  Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Authors:  Sven Rottenberg; Marieke A Vollebergh; Bas de Hoon; Jorma de Ronde; Philip C Schouten; Ariena Kersbergen; Serge A L Zander; Marina Pajic; Janneke E Jaspers; Martijn Jonkers; Martin Lodén; Wendy Sol; Eline van der Burg; Jelle Wesseling; Jean-Pierre Gillet; Michael M Gottesman; Joost Gribnau; Lodewyk Wessels; Sabine C Linn; Jos Jonkers; Piet Borst
Journal:  Cancer Res       Date:  2012-03-06       Impact factor: 12.701

6.  Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

Authors:  Ian J Majewski; René Bernards
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

7.  Challenges translating breast cancer gene signatures into the clinic.

Authors:  Britta Weigelt; Lajos Pusztai; Alan Ashworth; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2011-08-30       Impact factor: 66.675

Review 8.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.

Authors:  Peter Bouwman; Jos Jonkers
Journal:  Nat Rev Cancer       Date:  2012-09       Impact factor: 60.716

9.  Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.

Authors:  Marc Warmoes; Janneke E Jaspers; Guotai Xu; Bharath K Sampadi; Thang V Pham; Jaco C Knol; Sander R Piersma; Epie Boven; Jos Jonkers; Sven Rottenberg; Connie R Jimenez
Journal:  Mol Cell Proteomics       Date:  2013-02-08       Impact factor: 5.911

10.  Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance.

Authors:  Charlotte K Y Ng; Britta Weigelt; Roger A'Hern; Francois-Clement Bidard; Christophe Lemetre; Charles Swanton; Ronglai Shen; Jorge S Reis-Filho
Journal:  Cancer Res       Date:  2014-04-04       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.